SOLIRIS PATIENT CARD

Important Safety Information for Patients Taking SOLIRIS (eculizumab)

SOLIRIS can lower the ability of your immune system to fight infections, **especially meningococcal infection**, **which requires immediate medical attention**.

If you experience any of the following symptoms, you should **immediately call your doctor or seek emergency medical care, preferably in a major emergency medical care centre**:

- headache with nausea or vomiting
- headache with a stiff neck or back
- fever
- rash
- confusion
- severe muscle aches combined with flu-like symptoms
- sensitivity to light

Get emergency medical care right away if you have any of these signs or symptoms and show this card.

Keep this card with you at all times during treatment and for 3 months after your last SOLIRIS dose. Your risk of meningococcal infection may continue for several weeks after your last dose of SOLIRIS.

Information for Healthcare Professionals

- **This patient has been prescribed SOLIRIS (eculizumab), which increases the patient's susceptibility to meningococcal infection** *(Neisseria meningitidis)* **or other general infections**.
- All patients must be vaccinated at least 2 weeks prior to receiving SOLIRIS. Patients who initiate SOLIRIS less than 2 weeks after receiving meningococcal vaccine must receive appropriate prophylactic antibiotics until 2 weeks after vaccination.
- Patients must receive vaccination and revaccination according to current national vaccination guidelines for vaccination use.
- Meningococcal infections may become rapidly life-threatening or fatal if not recognised and treated early.
- **Evaluate immediately if infection is suspected and treat with appropriate antibiotics if necessary.**
- Contact prescribing physician (below) as soon as possible.

For more information about SOLIRIS, please refer to the full SOLIRIS (eculizumab) Summary of Product Characteristics or e-mail: medinfo-ksa@astrazeneca.com

Restricted - مقيد

In case of safety concerns, call AstraZeneca, Saudi Arabia:
Email: ksa.ae@astrazeneca.com
Phone: +966 11 2249235
Portal: https://contactazmedical.astrazeneca.com/
Or SFDA reporting information:
Email: npc.drug@sfda.gov.sa
Toll free phone: 19999
Portal: https: //ade.sfda.gov.sa

Patient name _____

Hospital where treated _____

Physician name _____

Tel. number _____

Vaccination date(s): _____

SOLIRIS Treatment Initiation Date:

Meningococcal Vaccination information:

Vaccine Brand	Vaccine Serogroup	Dose Number	Date	Primary Series/ Booster Dose	Antibiotic prophylaxis received if Soliris is initiated less than 2 weeks after receiving vaccine
					☐ Not Applicable ☐ Yes, start date: _____
					☐ Not Applicable ☐ Yes, start date: _____
					☐ Not Applicable ☐ Yes, start date: _____

Approved Nov 2026

Restricted - مقيد